Merus (MRUS) Price & Analysis

Compare

480 Followers

MRUS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$33.19 - $67.59

Previous CloseN/A

Volume56.75K

Average Volume (3M)621.91K

Market Cap

$4.88B

Enterprise Value$2.46B

Total Cash (Recent Filing)$458.32M

Total Debt (Recent Filing)$9.86M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Oct 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding74,476,730

10 Day Avg. Volume689,411

30 Day Avg. Volume621,907

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue44.88

Enterprise Value/Gross Profit44.88

Enterprise Value/Ebitda-7.30

Forecast

1Y Price Target

$94.70

Price Target Upside44.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe market for RAS/RAF-wildtype CRC is large, with an annual total addressable market of around $12 billion, which presents a significant opportunity.

Regulatory And Trial SuccessThe company is confident in the regulatory path for petosemtamab in head and neck squamous cell carcinoma, with phase 3 trials showing promising results in both HPV+ and HPV- patients.

Stock Price PotentialThe price objective for Merus NV stock is set at 92.00 USD, indicating significant potential upside from the current price.

Bears Say

Data Presentation ConcernsBCAX's presenter acknowledged that the 80% tumor reduction cut off to classify a 'deep' response was 'arbitrary.'

Investor SentimentPetosemtamab's opportunity remains unappreciated by investors, partially due to disappointing yet uninformative dose escalation data.

Merus News

Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment

Merus NV (($MRUS)) announced an update on their ongoing clinical study. Merus N.V. is conducting a Phase 3...

3d ago

MRUS

Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study

Merus NV (($MRUS)) announced an update on their ongoing clinical study. Merus N.V. is conducting a Phase 3...

17d ago

MRUS

Truist biotech analyst holds an analyst/industry conference call

Biotech Analyst Goonewardene discusses Gastrointestinal Cancer (relevant companies EXEL, MRUS, JNJ, RVMD) on an Analyst/Industry conference call to...

1M ago

JNJ

EXEL

Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment

Merus NV (($MRUS)) announced an update on their ongoing clinical study. Merus N.V. is conducting a Phase 1/2...

1M ago

MRUS

Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know

Merus NV (($MRUS)) announced an update on their ongoing clinical study. Merus N.V. is conducting a Phase 3...

1M ago

MRUS

3 Best Stocks to Buy Now, 6/12/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

ACMR

MRUS

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

Merus (MRUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

2M ago

MRUS

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

Merus (MRUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

2M ago

MRUS

Merus Announces Public Offering of Common Shares

Merus ( ($MRUS) ) has shared an update. On June 3, 2025, Merus N.V. entered into an underwriting...

2M ago

MRUS

Trump says Fed ‘must now’ lower rates after ADP payrolls report: Morning Buzz

The major averages were fractionally higher near noon as investors are focused on jobless claims and the May...

2M ago

BLK

Merus 5.27M share Spot Secondary priced at $57.00

Jefferies, BofA, Leerink, Guggenheim, Truist and LifeSci Capital acted as joint book running managers for the offering. Published...

2M ago

MRUS

Merus’s Promising Clinical Developments and Market Potential Justify Buy Rating

Analyst Tazeen Ahmad of Bank of America Securities maintained a Buy rating on Merus (MRUS – Research Report),...

2M ago

MRUS

Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise

In the opening 90 minutes of the evening session, U.S. equity futures are up marginally – S&P 500...

2M ago

HPE

HQY

Merus announces common shares offering, no amount given

Merus (MRUS) N.V. announced the launch of a proposed underwritten public offering of its common shares. All of...

2M ago

MRUS

MRUS FAQ

What was Merus NV’s price range in the past 12 months?

Merus NV lowest stock price was $33.19 and its highest was $67.59 in the past 12 months.

What is Merus NV’s market cap?

Merus NV’s market cap is $4.88B.

When is Merus NV’s upcoming earnings report date?

Merus NV’s upcoming earnings report date is Oct 30, 2025 which is in 88 days.

How were Merus NV’s earnings last quarter?

Currently, no data Available

Is Merus NV overvalued?

According to Wall Street analysts Merus NV’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Merus NV pay dividends?

Merus NV does not currently pay dividends.

What is Merus NV’s EPS estimate?

Merus NV’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Merus NV have?

Merus NV has 74,476,730 shares outstanding.

What happened to Merus NV’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Merus NV?

Currently, no hedge funds are holding shares in MRUS

Merus Stock Smart Score

Outperform

Fundamentals

Return on Equity

-58.66%

Trailing 12-Months

Asset Growth

46.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus (MRUS) Earnings & Revenues

MRUS Earnings Data >

MRUS Stock 12 Month Forecast

Average Price Target

$94.70

▲(44.45%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","111":"$111","56.25":"$56.3","74.5":"$74.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,56.25,74.5,92.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.66,57.07076923076923,61.48153846153846,65.8923076923077,70.30307692307693,74.71384615384616,79.12461538461538,83.53538461538461,87.94615384615385,92.35692307692308,96.76769230769231,101.17846153846153,105.58923076923077,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.66,55.89384615384615,59.12769230769231,62.36153846153846,65.59538461538462,68.82923076923078,72.06307692307692,75.29692307692308,78.53076923076924,81.76461538461538,84.99846153846154,88.2323076923077,91.46615384615384,{"y":94.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.66,53.76307692307692,54.86615384615384,55.96923076923077,57.07230769230769,58.175384615384615,59.278461538461535,60.38153846153846,61.48461538461538,62.58769230769231,63.69076923076923,64.79384615384615,65.89692307692307,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.45,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >